Skip to main content
Fig. 2 | Child and Adolescent Psychiatry and Mental Health

Fig. 2

From: Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial

Fig. 2

Overall changes in clinical symptoms between groups at Days 0, 6, and 12. A A significant decrease in MADRS score in both groups from baseline to Days 6 and 12. B A significant decrease in SSI-5 score in both groups from baseline to Days 6 and 12. Asterisk (*) represents significant difference between groups (*P < 0.05). MADRS Montgomery–Asberg Depression Rating Scale, SSI Beck Scale for Suicide Ideation

Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000